Quarterly ResultMay 5, 2026, 04:19 PM
Amwell Q1 Total Revenue $54.9M; Net Loss ($10.3M); Adj. EBITDA ($3.1M)
AI Summary
Amwell announced its financial results for the first quarter ended March 31, 2026, reporting total revenue of $54.9 million, which exceeded its financial guidance. The company showed a favorable trajectory in its financial performance, with a net loss of ($10.3) million and Adjusted EBITDA of ($3.1) million, both significantly improved from the previous quarter. Amwell reaffirmed its 2026 revenue guidance and updated its Adjusted EBITDA outlook, reiterating its objective to achieve positive cash flow from operations in the fourth quarter of 2026.
Key Highlights
- Q1 Total Revenue: $54.9 million, exceeding previously provided guidance.
- Q1 Subscription Revenue: $24.9 million.
- Q1 Amwell Medical Group (AMG) visit revenue: $28.9 million.
- Q1 Gross Margin: 51%.
- Q1 Net Loss: ($10.3) million, an improvement from ($25.2) million in Q4 2025.
- Q1 Adjusted EBITDA: ($3.1) million, an improvement from ($10.3) million in Q4 2025.
- Reaffirmed 2026 Revenue Guidance: $195 million to $205 million.
- Updated 2026 Adjusted EBITDA Guidance: ($16) million to ($12) million.
- Target: Positive cash flow from operations in Q4 2026.